Conatus axes staff after latest failure of Novartis-partnered NASH drugConatus has said it will have to cut around 40% of its workforce and jettison some pipeline projects Share XConatus axes staff after latest failure of Novartis-partnered NASH drughttps://pharmaphorum.com/news/conatus-axes-staff-after-latest-nash-trial-failure/
Novartis takes option on NASH drug from ConatusSwiss pharma takes option on FXR agonist emricasan. Share XNovartis takes option on NASH drug from Conatushttps://pharmaphorum.com/news/novartis-takes-option-nash/